Journal of Natural Medicines

, Volume 71, Issue 1, pp 123–130 | Cite as

5′-AMP-activated protein kinase plays an essential role in geniposide-regulated glucose-stimulated insulin secretion in rat pancreatic INS-1 β cells

  • Yanan Hao
  • Chunyan Liu
  • Fei Yin
  • Yonglan Zhang
  • Jianhui Liu
Original Paper


Our previous work showed that geniposide affected glucose-stimulated insulin secretion (GSIS) via regulating glucose uptake and metabolism in pancreatic β cells; however, the molecular mechanisms remain largely unknown. Substantial evidence suggests that activation of 5′-AMP-activated protein kinase (AMPK) plays a central role in GSIS. Here, we aim to determine the role of AMPK on geniposide-regulated GSIS in rat pancreatic INS-1 cells. The results demonstrated that 6-[4-(2-piperidin-1-yletoxy)-phenyl]-3-pyridin-4-yl-pyrazolo[1,5-α] pyrimidine (Compound C; an AMPK inhibitor) significantly attenuated the effects of geniposide on glucose uptake, energy metabolism, and insulin secretion in INS-1 cells. We also observed that geniposide induced phosphorylation of acetyl-CoA carboxylase (ACC), a marker of AMPK activity, in a time-dependent manner in INS-1 cells; however, in the presence of Compound C, the influence of geniposide on ACC phosphorylation was obviously inhibited. Furthermore, the knockdown of AMPK protein with AMPK siRNA treatment decreased the effects of geniposide on glucose uptake, adenosine triphosphate production, and GSIS. All these data indicate that AMPK plays an essential role in geniposide-regulated GSIS in pancreatic β cells.


Acetyl-CoA carboxylase (ACC) 5′-AMP-activated protein kinase (AMPK) Geniposide Glucose-stimulated insulin secretion (GSIS) 



This work was supported by grants from National Natural Science Foundation of China (81373459), Chongqing Science and Technology Committee (CSTC, 2015jcyjbx0064), Chongqing Science Found for Distinguished Young Scholars (2014jcyjjq10003), the Innovation of Science and Technology Leading Talent in Chongqing (2014kjcxljrc0018), and the Innovative Research Team Development Program at the University of Chongqing (CXTDX201601031).

Compliance with ethical standards

Conflict of interest

The authors disclose that there is no conflict of interest.


  1. 1.
    Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMedGoogle Scholar
  2. 2.
    Paneni F, Costantino S (2015) Mechanisms-based therapeutic strategies in type 2 diabetes. Cardiovasc Diagn Ther 5:340–342PubMedPubMedCentralGoogle Scholar
  3. 3.
    Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346CrossRefPubMedGoogle Scholar
  4. 4.
    DeFronzo RA (1997) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 50:191–197CrossRefPubMedGoogle Scholar
  5. 5.
    Woerle HJ, Carneiro L, Derani A, Goke B, Schirra J (2012) The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 61:2349–2358CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A (2015) Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion. Biochem J 466:203–218CrossRefPubMedGoogle Scholar
  7. 7.
    Gerdes JM, Christou-Savina S, Xiong Y, Moede T, Moruzzi N, Karlsson-Edlund P, Leibiger B, Leibiger IB, Ostenson CG, Beales PL, Berggren PO (2014) Ciliary dysfunction impairs beta-cell insulin secretion and promotes development of type 2 diabetes in rodents. Nat Commun 5:5308CrossRefPubMedGoogle Scholar
  8. 8.
    Zou CY, Gong Y, Liang J (2016) Metabolic signaling of insulin secretion by pancreatic beta-cell and its derangement in type 2 diabetes. Eur Rev Med Pharmacol Sci 20:391Google Scholar
  9. 9.
    Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E (1997) Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353–1356CrossRefPubMedGoogle Scholar
  10. 10.
    Chen JY, Wu H, Li H, Hu SL, Dai MM, Chen J (2015) Anti-inflammatory effects and pharmacokinetics study of geniposide on rats with adjuvant arthritis. Int Immunopharmacol 24:102–109CrossRefPubMedGoogle Scholar
  11. 11.
    Guo L, Zheng X, Liu J, Yin Z (2016) Geniposide suppresses hepatic glucose production via AMPK in HepG2 cells. Biol Pharm Bull 39:484–491CrossRefPubMedGoogle Scholar
  12. 12.
    Liu HT, He JL, Li WM, Yang Z, Wang YX, Yin J, Du YG, Yu C (2010) Geniposide inhibits interleukin-6 and interleukin-8 production in lipopolysaccharide-induced human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways. Inflamm Res 59:451–461CrossRefPubMedGoogle Scholar
  13. 13.
    Wu SY, Wang GF, Liu ZQ, Rao JJ, Lu L, Xu W, Wu SG, Zhang JJ (2009) Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin 30:202–208CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kojima K, Shimada T, Nagareda Y, Watanabe M, Ishizaki J, Sai Y, Miyamoto K, Aburada M (2011) Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells. Biol Pharm Bull 34:1613–1618CrossRefPubMedGoogle Scholar
  15. 15.
    Liu J, Yin F, Zheng X, Jing J, Hu Y (2007) Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 51:361–369CrossRefPubMedGoogle Scholar
  16. 16.
    Liu J, Zheng X, Yin F, Hu Y, Guo L, Deng X, Chen G, Jiajia J, Zhang H (2006) Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int J Dev Neurosci 24:419–424CrossRefPubMedGoogle Scholar
  17. 17.
    Liu JH, Yin F, Guo LX, Deng XH, Hu YH (2009) Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin 30:159–165CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhang Y, Yin F, Liu J, Liu Z, Guo L, Xia Z, Zidichouski J (2015) Geniposide attenuates insulin-deficiency-induced acceleration of beta-amyloidosis in an APP/PS1 transgenic model of Alzheimer’s disease. Neurochem Int 89:7–16CrossRefPubMedGoogle Scholar
  19. 19.
    Guo LX, Xia ZN, Gao X, Yin F, Liu JH (2012) Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cells. Acta Pharmacol Sin 33:237–241CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Guo L, Yin F, Zhang Y, Liu Z, Wang Y (2013) Geniposide regulates glucose-stimulated insulin secretion possibly through controlling glucose metabolism in INS-1 cells. PLoS One 8:e78315CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Guo LX, Liu JH, Yin F (2014) Regulation of insulin secretion by geniposide: possible involvement of phosphatidylinositol 3-phosphate kinase. Eur Rev Med Pharmacol Sci 18:1287–1294PubMedGoogle Scholar
  22. 22.
    Guo L, Liu CY, Yin F, Liu JH (2016) Possible role of AMPK/SIRT signaling on energy balance in geniposide-treated INS-1 cells. Med Chem 6:33–38CrossRefGoogle Scholar
  23. 23.
    Coughlan KA, Valentine RJ, Ruderman NB, Saha AK (2014) AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 7:241–253PubMedPubMedCentralGoogle Scholar
  24. 24.
    Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F (2009) Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed) 14:3380–3400CrossRefGoogle Scholar
  25. 25.
    Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407–416CrossRefPubMedGoogle Scholar
  26. 26.
    Peterson JM, Aja S, Wei Z, Wong GW (2012) CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem 287:1576–1587CrossRefPubMedGoogle Scholar
  27. 27.
    Fu A, Eberhard CE, Screaton RA (2013) Role of AMPK in pancreatic beta cell function. Mol Cell Endocrinol 366:127–134CrossRefPubMedGoogle Scholar
  28. 28.
    Salt IP, Johnson G, Ashcroft SJ, Hardie DG (1998) AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 335(Pt 3):533–539CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371:761–774CrossRefGoogle Scholar
  30. 30.
    Leclerc I, Rutter GA (2004) AMP-activated protein kinase: a new beta-cell glucose sensor?: regulation by amino acids and calcium ions. Diabetes 53(Suppl 3):S67–S74CrossRefPubMedGoogle Scholar
  31. 31.
    Mantovani J, Roy R (2011) Re-evaluating the general(ized) roles of AMPK in cellular metabolism. FEBS Lett 585:967–972CrossRefPubMedGoogle Scholar
  32. 32.
    Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ (2007) The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282:10341–10351CrossRefPubMedGoogle Scholar
  33. 33.
    Dufer M, Noack K, Krippeit-Drews P, Drews G (2010) Activation of the AMP-activated protein kinase enhances glucose-stimulated insulin secretion in mouse beta-cells. Islets 2:156–163CrossRefPubMedGoogle Scholar
  34. 34.
    Winder WW, Hardie DG (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277:E1–E10PubMedGoogle Scholar
  35. 35.
    Alves CR, Ferreira JC, de Siqueira-Filho MA, Carvalho CR, Lancha AH Jr, Gualano B (2012) Creatine-induced glucose uptake in type 2 diabetes: a role for AMPK-alpha? Amino Acids 43:1803–1807CrossRefPubMedGoogle Scholar
  36. 36.
    Hutchinson DS, Summers RJ, Bengtsson T (2008) Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther 119:291–310CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer Japan 2016

Authors and Affiliations

  • Yanan Hao
    • 1
  • Chunyan Liu
    • 1
  • Fei Yin
    • 1
  • Yonglan Zhang
    • 1
  • Jianhui Liu
    • 1
  1. 1.Chongqing Key Lab of Medicinal Chemistry and Molecular PharmacologyChongqing University of TechnologyChongqingChina

Personalised recommendations